Consensus LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2024 am IST			5-day change	1st Jan Change
5.47 ^USD	+3.60%		-4.87%	-30.14%

10/06	Transcript : LifeStance Health Group, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:00 AM
29/05	Lifestance Health Group Insider Sold Shares Worth $22,395,812, According to a Recent SEC Filing	MT

Evolution of the average Target Price on LifeStance Health Group, Inc.

Price target over the last 5 years

History of analyst recommendation changes

92e7b1d3a94e54e0f8bf3bf80bd35.PMW4cjWRIwqMg2ecZ9B09H5E-JEpBxhDwLbTdxdmOlk.BaTQH1z_GmnO8jDIDYIsgx0NjPtgf0gVp_H-QCYiahtotforevdhfd3wCA~388ff794abca0484d96ceaddeac40f38

Analyst Recommendations on LifeStance Health Group, Inc.

Lifestance Health Group Insider Sold Shares Worth $22,395,812, According to a Recent SEC Filing	30/05	MT
Lifestance Health Group Insider Sold Shares Worth $9,569,118, According to a Recent SEC Filing	30/05	MT
LifeStance Health Group Prices Secondary Stock Offering; Shares Plunge Premarket	22/05	MT
LifeStance Health Discloses Secondary Public Offering	22/05	MT
Lifestance Health Group Insider Sold Shares Worth $362,567, According to a Recent SEC Filing	15/05	MT
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	06/03	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating	04/03	MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating	29/02	MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating	29/02	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $8 From $9, Maintains Neutral Rating	22/11	MT
JPMorgan Adjusts LifeStance Health Group's Price Target to $8 From $10, Maintains Neutral Rating	17/11	MT
UBS Cuts LifeStance Health Group's Price Target to $7 From $10, Keeps Neutral Rating	09/11	MT
Goldman Sachs Adjusts LifeStance Health Group's Price Target to $9 From $8, Keeps Neutral Rating	19/23/19	MT
UBS Adjusts LifeStance Health Price Target to $10 From $7, Maintains Neutral Rating	12/23/12	MT
Morgan Stanley Adjusts Price Target on LifeStance Health to $10 From $8, Maintains Overweight Rating	11/23/11	MT
UBS Adjusts Price Target on LifeStance Health to $7 From $6.50, Maintains Neutral Rating	09/23/09	MT
Morgan Stanley Upgrades LifeStance Health Group to Overweight From Equalweight With $8 Price Target	06/23/06	MT
Goldman Sachs Trims Price Target on LifeStance Health Group to $8 From $9, Maintains Neutral Rating	15/22/15	MT
Cowen Trims Price Target on LifeStance Health Group to $8 From $10, Maintains Outperform Rating	14/22/14	MT
UBS Adjusts LifeStance Health Group Price Target to $6.50 From $7, Maintains Neutral Rating	09/22/09	MT
Jefferies Assumes LifeStance Health at Buy Rating With $7.25 Price Target	07/22/07	MT
Cowen Adjusts Price Target on LifeStance Health Group to $10 From $11, Keeps Outperform Rating	22/22/22	MT
Jefferies Lowers Price Target for LifeStance Health Group to $10 From $15, Maintains Buy Rating	10/22/10	MT
JPMorgan Adjusts Price Target for LifeStance Health Group to $9 From $12, Maintains Neutral Rating	10/22/10	MT
Morgan Stanley Adjusts LifeStance Health Group's Price Target to $8 from $10, Keeps Equalweight Rating	10/22/10	MT